NBIX - Neurocrine Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
79.44
+1.28 (+1.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close78.16
Open78.45
Bid0.00 x 0
Ask0.00 x 0
Day's Range77.94 - 79.98
52 Week Range41.76 - 92.98
Volume537,544
Avg. Volume789,343
Market Cap7.14B
Beta2.08
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1995-12-29
1y Target EstN/A
Trade prices are not sourced from all markets
  • What Analysts Recommend for Neurocrine Biosciences in April 2018
    Market Realist10 hours ago

    What Analysts Recommend for Neurocrine Biosciences in April 2018

    In April 2018, the US FDA (Food and Drug Administration) notified Neurocrine Biosciences and AbbVie (ABBV) that it would require more time to review additional information associated with the liver function tests provided by AbbVie in addition to it its NDA (new drug application) for Elagolix. The US FDA granted the new PDUFA (Prescription Drug Fee User Act) action date in 3Q18.

  • How Neurocrine Biosciences Is Positioned ahead of 1Q18 Earnings
    Market Realist12 hours ago

    How Neurocrine Biosciences Is Positioned ahead of 1Q18 Earnings

    How Neurocrine Biosciences Is Positioned ahead of 1Q18 EarningsNeurocrine Biosciences revenue trends

  • Ingrezza: Boosting Neurocrine’s Top Line
    Market Realist15 days ago

    Ingrezza: Boosting Neurocrine’s Top Line

    Neurocrine Biosciences (NBIX) is a pharmaceutical company with a focus on neurological and endocrine-based diseases and disorders. Its leading product on the market is Ingrezza, a vesicular monoamine transporter 2 (or VMAT2) inhibitor used in the treatment of movement disorders. Ingrezza was approved by the FDA for the treatment of tardive dyskinesia (or TD) in April 2017.

  • Reuters17 days ago

    FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

    AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said.

  • Reuters17 days ago

    FDA extends review for AbbVie, Neurocrine's uterine pain drug

    AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said. The FDA is now expected to make its decision in the third quarter of 2018, three months later than initially expected.

  • Forbes17 days ago

    A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star

    Who's the world's best hedge fund manager? David Tepper? Stevie Cohen? Try Joe Edelman, a wannabe psychologist with a bead on biotech who has quietly built the best track record of the past two decades.

  • See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

    Neurocrine Biosciences Inc NASDAQ/NGS:NBIX

  • See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
    Markit22 days ago

    See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

    Neurocrine Biosciences Inc NASDAQ/NGS:NBIX

  • 3 Biotechs That Could Get Big Boosts in April
    Motley Foollast month

    3 Biotechs That Could Get Big Boosts in April

    April showers might bring May flowers. But they also bring major FDA decisions for these biotechs.

  • How Is Teva Progressing with Its Specialty Assets Portfolio?
    Market Realistlast month

    How Is Teva Progressing with Its Specialty Assets Portfolio?

    Teva Pharmaceutical (TEVA) is focused on advancing its specialty assets portfolio, one of its key growth drivers. The company’s specialty products portfolio is made up of Copaxone, Austedo, Fremanezumab, and a number of other assets that are in clinical trials, one of which is Fasinumab.

  • Loss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX) Expected To Breakeven
    Simply Wall St.last month

    Loss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX) Expected To Breakeven

    Neurocrine Biosciences Inc’s (NASDAQ:NBIX): Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The US$7.85B market-cap company announcedRead More...

  • Is This AbbVie's Next Blockbuster Drug?
    Motley Foollast month

    Is This AbbVie's Next Blockbuster Drug?

    Another positive phase 3 trial may position endometriosis-pain treatment candidate elagolix as a future billion-dollar seller.

  • See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

    Neurocrine Biosciences Inc NASDAQ/NGS:NBIX

  • MarketWatch2 months ago

    AbbVie, Neurocrine shares rise after positive results for uterine fibroids drug

    AbbVie Inc. and Neurocrine Biosciences Inc. shares rose 1.7% and 1.1% respectively in premarket trade Wednesday after the companies announced that their drug met its primary endpoint in a phase 3 trial ...

  • Investopedia2 months ago

    5 Stocks to Outperform in 2018’s Volatile Market

    TipRanks, which ranks analysts' recommendations, has picked a handful of stocks as safe bets.

  • Zacks Small Cap Research2 months ago

    NBIX: Will File an NDA for Opicapone in 1H19

    On Feb. 14, 2018, Neurocrine Biosciences, Inc. (NBIX) announced the company will file a new drug application (NDA) for opicapone in the first half of 2019 following receipt of the meeting minutes from the January 2018 meeting with the FDA. During that meeting, the FDA did not request that Neurocrine conduct an additional Phase 3 study for opicapone prior to filing the NDA. Opicapone is a peripherally-acting and highly selective inhibitor of catechol-o-methyltransferase (COMT) to be used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors in patients with Parkinson’s disease (PD).

  • See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of NBIX earnings conference call or presentation 13-Feb-18 10:00pm GMT

    Q4 2017 Neurocrine Biosciences Inc Earnings Call

  • Associated Press2 months ago

    Neurocrine misses 4Q profit forecasts

    The San Diego-based company said it had profit of 7 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings ...

  • GuruFocus.com3 months ago

    Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $8.5 million of Shares

    CEO of Neurocrine Biosciences Inc (NASDAQ:NBIX) Kevin Charles Gorman sold 105,983 shares of NBIX on 02/06/2018 at an average price of $80.25 a share.

  • Comparing Cara Therapeutics’ Financial Performance
    Market Realist3 months ago

    Comparing Cara Therapeutics’ Financial Performance

    What's in Store for Cara Therapeutics in 2018?

  • Cara Therapeutics’ Collaboration Agreements
    Market Realist3 months ago

    Cara Therapeutics’ Collaboration Agreements

    What's in Store for Cara Therapeutics in 2018?

  • An Insight into Cara Therapeutics’ Drug Pipeline
    Market Realist3 months ago

    An Insight into Cara Therapeutics’ Drug Pipeline

    Cara Therapeutics’ (CARA) investigational drug candidate, CR845, is being developed for providing pain relief. Intravenous (or IV) CR845 has shown a pain relief and tolerability profile in three Phase 2 clinical trials in patients with acute postoperative pain. Cara Therapeutics has initiated a Phase 3 clinical trial program for IV CR845 for postoperative pain in patients undergoing a range of abdominal surgeries.

  • Analysts’ Recommendations for Cara Therapeutics in January 2018
    Market Realist3 months ago

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients. The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29.

  • Elagolix May Advance the Treatment Paradigm in Women’s Health
    Market Realist3 months ago

    Elagolix May Advance the Treatment Paradigm in Women’s Health

    On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.